

The Manager  
 Companies Announcement Platform  
 SIM Venture Securities Exchange

5 April 2013

## SoloFlow® Outperforms Competitors in Recent ISO Test


### HIGHLIGHTS:

- SoloFlow® outperforms competitors in recent fragmentation tests (ISO 7864)
- Telezon® has developed anti-coring needle that can resolve coring issues
- Anti-coring needles for vial access typically sold at a premium

The Board of Telezon® is pleased to inform the market that the SoloFlow® needle has exceeded expectations, in recent preliminary results, demonstrating that the SoloFlow® **does not generate any fragments** after insertion into a vial rubber stopper. A typical steel hypodermic needle generated four times the number of fragments.

This significant result means that Telezon® has not only developed an anti-coring needle that can resolve coring issues, thereby reducing the potential risk to the patient during injection<sup>^</sup>; but it also can **compete healthily** with competitors who offer anti-coring vial access needles which are typically sold at a premium.

### Fragmentation Testing (ISO 7864)



As part of this recent report, Telezon® Ltd conducted preliminary studies to assess the number of fragments (or "coring") that occurs following insertion of its SoloFlow® needle into a vial rubber stopper, compared to other needle types. A rubber stopper is commonly used to seal glass vials that contain vaccines or medication. Prior to the administration of vaccines or medication, the vial is accessed through the rubber stopper with a hypodermic needle or a similar vial access device.

Fragmentation tests are carried out to measure the number of fragments (or "coring") generated by needles following the insertion to a rubber stopper. Sometimes, a small piece of the stopper can be sheared off following needle insertion. This piece of rubber can be pushed through to the liquid medication and subsequently can be injected into the patient<sup>i</sup>. Although coring most likely occurs infrequently, studies have recognised it to be a potential health hazard with serious implications for the patient<sup>^</sup>. Furthermore, patent applications to prevent coring would also suggest that coring is still an issue in markets globally.

For and on behalf of Telezon Limited,

Dr Michelle Carr  
Director & Co. Secretary  
T: +61 3 9763 8605 F: +61 3 9763 2714



Want to be one of the first to receive Telezon updates?  
[Click here](#) then register your details.



To visit our website, [click here](#) or visit:  
[www.telezon.com](http://www.telezon.com)



[Click here](#) to like us on Facebook - it's another way we're sharing company news with our shareholders and investors.

---

<sup>i</sup> \*Roth, J.V., "How to enter a medication vial without coring", Vol. 104, No. 6, June 2007, International Anesthesia Research Society